Supplementary Figure 2 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Bo Dong,Xiang Song,Xinzhao Wang,Tao Dai,Jianlin Wang,Zhiyong Yu,Jiong Deng,B. Mark Evers,Yadi Wu

DOI: https://doi.org/10.1158/1541-7786.24709915.v1

2023-01-01

Abstract:FBXO24 degrades LSD1.

What problem does this paper attempt to address?

Supplementary Figure 1 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Bo Dong,Xiang Song,Xinzhao Wang,Tao Dai,Jianlin Wang,Zhiyong Yu,Jiong Deng,B. Mark Evers,Yadi Wu

DOI: https://doi.org/10.1158/1541-7786.24709918.v1

2023-01-01

Abstract:FBXO24 regulates LSD1 at protein levels.
Supplemental Figure 4 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Bo Dong,Xiang Song,Xinzhao Wang,Tao Dai,Jianlin Wang,Zhiyong Yu,Jiong Deng,B. Mark Evers,Yadi Wu

DOI: https://doi.org/10.1158/1541-7786.24709921.v1

2023-01-01

Abstract:The expression of FBXO24 is inversely associated with the expression of LSD1.
Supplementary Figure 6 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Bo Dong,Xiang Song,Xinzhao Wang,Tao Dai,Jianlin Wang,Zhiyong Yu,Jiong Deng,B. Mark Evers,Yongqi Wu

DOI: https://doi.org/10.1158/1541-7786.24709906.v1

2023-01-01

Abstract:FBXO24 expression is associated with a good prognosis.
Supplementary Figure 5 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Bo Dong,Xiang Song,Xinzhao Wang,Tao Dai,Jianlin Wang,Zhiyong Yu,Jiong Deng,B. Mark Evers,Yadi Wu

DOI: https://doi.org/10.1158/1541-7786.24709909.v1

2023-01-01

Abstract:Association between FBXO24 expression and tumor stage and overall survival (OS) in the TCGA dataset.
Data from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Bo Dong,Xiang Song,Xinzhao Wang,Tao Dai,Jianlin Wang,Zhiyong Yu,Jiong Deng,B. Mark Evers,Yadi Wu

DOI: https://doi.org/10.1158/1541-7786.c.6960436.v1

2023-01-01

Abstract:AbstractLysine-specific demethylase 1 (LSD1), a critical chromatin modulator, functions as an oncogene by demethylation of H3K4me1/2. The stability of LSD1 is governed by a complex and intricate process involving ubiquitination and deubiquitination. Several deubiquitinases preserve LSD1 protein levels. However, the precise mechanism underlying the degradation of LSD1, which could mitigate its oncogenic function, remains unknown. To gain a better understanding of LSD1 degradation, we conducted an unbiased siRNA screening targeting all the human SCF family E3 ligases. Our screening identified FBXO24 as a genuine E3 ligase that ubiquitinates and degrades LSD1. As a result, FBXO24 inhibits LSD1-induced tumorigenesis and functions as a tumor suppressor in breast cancer cells. Moreover, FBXO24 exhibits an inverse correlation with LSD1 and is associated with a favorable prognosis in breast cancer patient samples. Taken together, our study uncovers the significant role of FBXO24 in impeding breast tumor progression by targeting LSD1 for degradation.Implications:Our study provides comprehensive characterization of the significant role of FBXO24 in impeding breast tumor progression by targeting LSD1 for degradation.
FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination.

Bo Dong,Xiang Song,Xinzhao Wang,Tao Dai,Jianlin Wang,Zhiyong Yu,Jiong Deng,B Mark Evers,Yadi Wu

DOI: https://doi.org/10.1158/1541-7786.MCR-23-0169

2023-01-01

Abstract:Lysine-specific demethylase 1 (LSD1), a critical chromatin modulator, functions as an oncogene by demethylation of H3K4me1/2. The stability of LSD1 is governed by a complex and intricate process involving ubiquitination and deubiquitination. Several deubiquitinases preserve LSD1 protein levels. However, the precise mechanism underlying the degradation of LSD1, which could mitigate its oncogenic function, remains unknown. To gain a better understanding of LSD1 degradation, we conducted an unbiased siRNA screening targeting all the human SCF family E3 ligases. Our screening identified FBXO24 as a genuine E3 ligase that ubiquitinates and degrades LSD1. As a result, FBXO24 inhibits LSD1-induced tumorigenesis and functions as a tumor suppressor in breast cancer cells. Moreover, FBXO24 exhibits an inverse correlation with LSD1 and is associated with a favorable prognosis in breast cancer patient samples. Taken together, our study uncovers the significant role of FBXO24 in impeding breast tumor progression by targeting LSD1 for degradation. IMPLICATIONS:Our study provides comprehensive characterization of the significant role of FBXO24 in impeding breast tumor progression by targeting LSD1 for degradation.
Table S4 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Bo Dong,Xiang Song,Xinzhao Wang,Tao Dai,Jianlin Wang,Zhiyong Yu,Jiong Deng,B. Mark Evers,Yadi Wu

DOI: https://doi.org/10.1158/1541-7786.24709894.v1

2023-01-01

Abstract:Supplemental table 4. Tumor samples with Lymph node metastases of breast cancer.
Table S2 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Bo Dong,Xiang Song,Xinzhao Wang,Tao Dai,Jianlin Wang,Zhiyong Yu,Jiong Deng,B. Mark Evers,Yadi Wu

DOI: https://doi.org/10.1158/1541-7786.24709900.v1

2023-01-01

Abstract:The sequence of primers for RT-qPCR and ChIP-qPCR.
LSD1 Destabilizes FBXW7 and Abrogates FBXW7 Functions Independent of Its Demethylase Activity

Huiyin Lan,Mingjia Tan,Qiang Zhang,Fei Yang,Siyuan Wang,Hua Li,Xiufang Xiong,Yi Sun

DOI: https://doi.org/10.1073/pnas.1902012116

IF: 11.1

2019-01-01

Proceedings of the National Academy of Sciences

Abstract:FBXW7 acts as a typical tumor suppressor, with loss-of-function alterations in human cancers, by promoting ubiquitylation and degradation of many oncoproteins. Lysine-specific demethylase 1 (LSD1) is a well-characterized histone demethylase. Whether LSD1 has demethylase-independent activity remains elusive. Here we report that LSD1 directly binds to FBXW7 to destabilize FBXW7 independent of its demethylase activity. Specifically, LSD1 is a pseudosubstrate of FBXW7 and LSD1-FBXW7 binding does not trigger LSD1 ubiquitylation, but instead promotes FBXW7 self-ubiquitylation by preventing FBXW7 dimerization. The self-ubiquitylated FBXW7 is subjected to degradation by proteasome as well as lysosome in a manner dependent on autophagy protein p62/SQSTM1. Biologically, LSD1 destabilizes FBXW7 to abrogate its functions in growth suppression, nonhomologous end-joining repair, and radioprotection. Collectively, our study revealed a previously unknown activity of LSD1, which likely contributes to its oncogenic function. Targeting LSD1 protein, not only its demethylase activity, might be a unique approach for LSD1-based drug discovery for anticancer application.
LSD1 Destabilizes FBXW7 Independent of Its Demethylase Activity

Huiyin Lan,Mingjia Tan,Qiang Zhang,Fei Yang,Hua Li,Xiufang Xiong,Yi Sun

DOI: https://doi.org/10.2139/ssrn.3281653

2018-01-01

Abstract:FBXW7 acts as a typical tumor suppressor, with loss of function alterations in human cancers, by promoting ubiquitylation and degradation of many oncoproteins. Lysine-specific demethylase 1 (LSD1) is a well-characterized histone demethylase. Whether LSD1 has demethylase-independent activity remains elusive. Here we report that LSD1 directly binds to FBXW7 to destabilize FBXW7 independent of its demethylase activity. Specifically, LSD1 is a pseudo-substrate of FBXW7 and LSD1-FBXW7 binding does not trigger LSD1 ubiquitylation, instead promote FBXW7 self-ubiquitylation by preventing FBXW7 dimerization. The self-ubiquitylated FBXW7 is subjected to degradation by proteasome and lysosome in a manner dependent of autophagy protein p62/SQSTM1. Biologically, LSD1 destabilizes FBXW7 to abrogate its functions in growth suppression, NHEJ repair and radioprotection. Collectively, our study revealed a previously unknown activity of LSD1, which likely contributes to its oncogenic function. Targeting LSD1 protein, rather than its demethylase activity, might be a unique approach for LSD1-based drug discovery for anti-cancer application.
LSD1 Knockdown Reveals Novel Histone Lysine Methylation in Human Breast Cancer MCF-7 Cells

Yue Jin,Bo Huo,Xueqi Fu,Zhongyi Cheng,Jun Zhu,Yu Zhang,Tian Hao,Xin Hu

DOI: https://doi.org/10.1016/j.biopha.2017.05.106

IF: 7.419

2017-01-01

Biomedicine & Pharmacotherapy

Abstract:Histone lysine methylation, which plays an important role in the regulation of gene expression, genome stability, chromosome conformation and cell differentiation, is a dynamic process that is collaboratively regulated by lysine methyltransferases (KMTs) and lysine demethylases (KDMs). LSD1, the first identified KDMs, catalyzes the demethylation of mono- and di-methylated H3K4 and H3K9. Here, we systematically investigated the effects of LSD1 knockdown on histone methylations. Surprisingly, in addition to H3K4 and H3K9, the methylation level on other histone lysines, such as H3K27, H3K36 and H3K79, are also increased. The expression of SOX2, E-cadherin and FoxA2 are increased upon LSD1 knockdown, and the methylation level of H3K4, H3K27 and H3K36 in the promoter region of these genes are all changed after LSD1 knockdown. Our results show that LSD1 knockdown has a broad effect on histone lysine methylation, which indicates that LSD1 regulates histone lysine methylation in collaboration with other KMTs and KDMs.
Supplementary Figure 1 from Binding of the JmjC Demethylase JARID1B to LSD1/NuRD Suppresses Angiogenesis and Metastasis in Breast Cancer Cells by Repressing Chemokine CCL14

Qian Li,Lei Shi,Bin Gui,Wenhua Yu,Jiamu Wang,Di Zhang,Xiao Han,Zhi Yao,Yongfeng Shang

DOI: https://doi.org/10.1158/0008-5472.22388579

2023-01-01

Abstract:<p>PDF file - 57K</p>
The Deubiquitinase USP28 Stabilizes LSD1 and Confers Stem-Cell-like Traits to Breast Cancer Cells

Yadi Wu,Yifan Wang,Xiuwei H. Yang,Tiebang Kang,Yongxiang Zhao,Chi Wang,B. Mark Evers,Binhua P. Zhou

DOI: https://doi.org/10.1016/j.celrep.2013.08.030

IF: 8.8

2013-01-01

Cell Reports

Abstract:LSD1 is a critical chromatin modulator that controls cellular pluripotency and differentiation through the demethylation of H3K4me1/2. Overexpression of LSD1 has been observed in many types of tumors and is correlated with its oncogenic effects in tumorigenesis. However, the mechanism leading to LSD1 upregulation in tumors remains unclear. Using an unbiased siRNA screening against all the human deubiquitinases, we identified USP28 as a bona fide deubiquitinase of LSD1. USP28 interacted with and stabilized LSD1 via deubiquitination. USP28 overexpression correlated with LSD1 upregulation in multiple cancer cell lines and breast tumor samples. Knockdown of USP28 resulted in LSD1 destabilization, leading to the suppression of cancer stem cell (CSC)-like characteristics in vitro and inhibition of tumorigenicity in vivo, which can be rescued by ectopic LSD1 expression. Our study reveals a critical mechanism underlying the epigenetic regulation by USP28 and provides another treatment approach against breast cancer.
LSD1 Promotes Prostate Cancer Cell Survival by Destabilizing FBXW7 at Post-Translational Level

Xu-ke Qin,Yang Du,Xiu-heng Liu,Lei Wang

DOI: https://doi.org/10.3389/fonc.2020.616185

IF: 4.7

2021-01-01

Frontiers in Oncology

Abstract:Prostate cancer (PCa) is the most common cancer in men and the fifth leading cause of cancer death worldwide. Unfortunately, castration-resistant prostate cancer (CRPCa) is incurable with surgical treat and prone to drug resistance. Therefore, it is of great importance to find a new target for treatment. LSD1 is up-regulated in PCa and related with prognosis. The high-expression LSD1 has been shown to be a potential target for treatment and is widely studied for its demethylase-activity. However, its demethylation-independent function remains to be elusive in PCa. Recent study shows that LSD1 can destabilize cancer suppressor protein FBXW7 without demethylation-function. Hence, we hope to investigate the impact of non-canonical function of LSD1 on PCa cell survival. We over-expressed FBXW7 gene through plasmid vector in LNCaP and PC3 cell lines and the result shows that up-regulated FBXW7 can suppress the viability of PC cell through suppressing oncoproteins, such as c-MYC, NOTCH-1. After FBXW7 function experiment on PC cell, we knock-down LSD1 gene in the same kinds of cell lines. In western blot assay, we detected that down-regulation of LSD1 will cause the increasing of FBXW7 protein level and decreasing of its targeting oncoproteins. And mRNA level of FBXW7 did not change significantly after LSD1 knock-down, which means LSD1 may destabilize FBXW7 by protein-protein interactions. Moreover, exogenous wild type LSD1 and catalytically deficient mutant K661A both can abrogate previous effect of LSD1 knock-down. Consequently, LSD1 may promote PC cell survival by destabilizing FBXW7 without its demethylase-activity. Next, we compared two kinds inhibitors, and found that SP-2509 (Allosteric inhibitor) treatment suppress the cancer cell survival by blocking the LSD1–FBXW7 interaction, which is an effect that GSK-2879552 (catalytic inhibitor) cannot achieve. This work revealed a pivotal function of LSD1 in PCa, and indicated a new direction of LSD1 inhibitor research for PCa treatment.
Supplementary Data from FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression

Rui Sun,Hong-Yan Xie,Jin-Xian Qian,Yan-Ni Huang,Fan Yang,Fang-Lin Zhang,Zhi-Min Shao,Da-Qiang Li

DOI: https://doi.org/10.1158/0008-5472.22419813.v1

2023-01-01

Abstract:The Supplementary Information includes: Figure S1. The effects of FBXO22 on breast cancer cell proliferation and anchorage-independent 3D growth. Figure S2. FBXO22 promotes xenograft tumor growth of MDA-MB-231 cells in vivo. Figure S3. FBXO22 suppresses cell migration and invasion. Figure S4. The effects of FBXO22 on the expression levels of EMT markers. Figure S5. The effects of FBXO22 on the mRNA levels of SNAIL. Figure S6. Schematic diagram of the structural domains of FBXO22 and SNAIL proteins. Figure S7. Phosphorylation of SNAIL by GSK3β affects its stability and subcellular localization. Figure S8. The mutation pattern of FBXO22 in breast cancer. Figure S9. The effects of deletion of F-box domain or W52R mutation on subcellular localization of FBXO22 and protein stability of SNAIL. Figure S10. The proposed working model. Table S1. Characterization of clincopathological features of 164 primary breast cancer patients. Table S2. siRNA target sequences for GSK3β. Tables S3. Primers used for molecular cloning of expression vectors. Tables S4. Information of expression vectors used in this study. Tables S5. Information for primary antibodies used in this study. Tables S6. Primers used for qPCR analysis. Table S7. Correlation between FBXO22 expression and clincopathological factors in 164 primary breast cancer patients. Table S8. Multivariate analysis of clincopathological factors for OS and DFS in 164 primary breast cancer patients.
OTUD7B Deubiquitinates LSD1 to Govern Its Binding Partner Specificity, Homeostasis, and Breast Cancer Metastasis

Zhicheng Gong,Aicun Li,Jiancheng Ding,Qing Li,Lei Zhang,Yuanpei Li,Zhe Meng,Fei Chen,Jialiang Huang,Dawang Zhou,Ronggui Hu,Jing Ye,Wen Liu,Han You

DOI: https://doi.org/10.1002/advs.202004504

IF: 15.1

2021-05-29

Advanced Science

Abstract:<p>Genomic amplification of OTUD7B is frequently found across human cancers. But its role in tumorigenesis is poorly understood. Lysine-specific demethylase 1 (LSD1) is known to execute epigenetic regulation by forming corepressor complex with CoREST/histone deacetylases (HDACs). However, the molecular mechanisms by which cells maintain LSD1/CoREST complex integrity are unknown. Here, it is reported that LSD1 protein undergoes K63-linked polyubiquitination. OTUD7B is responsible for LSD1 deubiquitination at K226/277 residues, resulting in dynamic control of LSD1 binding partner specificity and cellular homeostasis. OTUD7B deficiency increases K63-linked ubiquitination of LSD1, which disrupts LSD1/CoREST complex formation and targets LSD1 for p62-mediated proteolysis. Consequently, OTUD7B deficiency impairs genome-wide LSD1 occupancy and enhances the methylation of H3K4/H3K9, therefore profoundly impacting global gene expression and abrogating breast cancer metastasis. Moreover, physiological fluctuation of OTUD7B modulates cell cycle-dependent LSD1 oscillation, ensuring the G1/S transition. Both OTUD7B and LSD1 proteins are overpresented in high-grade or metastatic human breast cancer, while dysregulation of either protein is associated with poor survival and metastasis. Thus, OTUD7B plays a unique partner-switching role in maintaining the integrity of LSD1/CoREST corepressor complex, LSD1 turnover, and breast cancer metastasis.</p>

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Targeting FBXO22 enhances radiosensitivity in non-small cell lung cancer by inhibiting the FOXM1/Rad51 axis

Yunshang Chen,Yun Zhou,Xue Feng,Zilong Wu,Yongqiang Yang,Xinrui Rao,Rui Zhou,Rui Meng,Xiaorong Dong,Shuangbing Xu,Sheng Zhang,Gang Wu,Xiaohua Jie

DOI: https://doi.org/10.1038/s41419-024-06484-1

2024-02-01

Cell Death and Disease

Abstract:Radioresistance is a major constraint on the efficacy of lung cancer radiotherapy, but its mechanism has not been fully elucidated. Here, we found that FBXO22 was aberrantly highly expressed in lung cancer and that FBXO22 knockdown increased the radiosensitivity of lung cancer cells. Mechanistically, FBXO22 promoted Rad51 gene transcription by increasing the level of FOXM1 at the Rad51 promoter, thereby inducing the formation of lung cancer radioresistance. Furthermore, we found that deguelin, a potential inhibitor of FBXO22, enhanced radiosensitivity in an FBXO22/Rad51-dependent manner and was safely tolerated in vivo. Collectively, our results illustrate that FBXO22 induces lung cancer radioresistance by activating the FOXM1/Rad51 axis and provide preclinical evidence for the clinical translation of this critical target.

cell biology
E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination

Hongge Zhu,Xiuli Wang,Xin Zhou,Suqiong Lu,Guomin Gu,Chunling Liu

DOI: https://doi.org/10.1038/s41374-022-00812-9

IF: 5.511

2022-11-01

Laboratory Investigation

Abstract:Non-small cell lung cancer (NSCLC) has high rates of morbidity and mortality. E3 ubiquitin ligase usually has antitumor effects. This study evaluated the mechanism of E3 ligase FBXW7 (F-box and WD repeat domain containing 7) in the radiosensitivity of NSCLC. NCI-H1299 and NCI-H1299R cells were irradiated by 0, 2, 4, and 6 Gy doses of X-ray, respectively. In addition to the measurement of cell proliferation, apoptosis, and γ-H2AX, FBXW7 expression was measured and the interaction between FBXW7 and SOX9 (SRY-box transcription factor 9) was evaluated. Ubiquitination level and protein stability of SOX9 were examined after FBXW7 overexpression. The binding relationship between SOX9 and CDKN1A (cyclin-dependent kinase inhibitor 1A) was verified. Xenograft tumor model was established to evaluate the effect of FBXW7 on radiosensitivity in vivo. FBXW7 was under-expressed in radioresistant cells. Overexpression of FBXW7 repressed NCI-H1299 and NCI-H1299R cell proliferation and colony formation and increased γ-H2AX-positive foci. Overexpression of FBXW7 increased the ubiquitination level and reduced the protein stability of SOX9. SOX9 bound to the CDKN1A promoter to inhibit CDKN1A expression. FBXW7 inhibited tumorigenesis and apoptosis and enhanced radiosensitivity of NSCLC cells in vivo via the SOX9/CDKN1A axis. Overall, FBXW7 inhibited SOX9 expression by promoting SOX9 ubiquitination and proteasome degradation, suppressing the binding of SOX9 to CDKN1A, and upregulating CDKN1A, thereby improving the radiosensitivity of NSCLC cells.

pathology,medicine, research & experimental
Abstract 4544: FBW7 Induces S-phase Arrest Caused by DNA Double Strand Breaks Through Targeting SOX9 for Proteasomal Degradation

Xuehui Hong,Wenyu Liu,Ruipeng Song,Hiroyuki Inuzuka,Hatem E. Sabaawy,Katherine M. Morgan,Jamie J. Shah,Samuel F. Bunting,Xing Feng,Chi-Kwan Tsang,Zhiyuan Shen,X. F. Steven Zheng,LianXin Liu,Sharon R. Pine

DOI: https://doi.org/10.1158/1538-7445.am2016-4544

IF: 11.2

2016-01-01

Cancer Research

Abstract:Abstract SOX9 encodes a transcription factor that governs cell fate specification throughout development and tissue homeostasis. Elevated SOX9 is implicated in the genesis or progression of many human tumors through increasing cell proliferation and epithelial-mesenchymal transition. We observed that, in response to UV irradiation or certain chemotherapeutic agents, SOX9 is actively and rapidly degraded by a ubiquitin pathway dependent mechanism across several different tumor types including lung cancer, colon cancer, osteosarcoma and melanoma, as well as normal human bronchial epithelial cells. We found that SOX9 is phosphorylated by GSK3β at Ser-236, facilitating the direct binding and degradation of SOX9 via the F box protein, FBW7α. We also determined that the de-ubiquitinase, USP28, stabilizes SOX9 under normal conditions by sequestering FBW7, but is released from FBW7 after UV irradiation, allowing FBW7 to bind SOX9 and target it for destruction. DNA damage-induced SOX9 degradation was independent of p53, ATM, ATR and MAPK pathways. Failure to deplete SOX9 attenuated the DNA damage-induced intra-S-phase checkpoint and increased long-term cell survival. Moreover, mutations within the FBW7 phosphodegron binding site of SOX9 prevented SOX9 degradation after DNA damage, and incurred resistance of non-small cell lung cancer (NSCLC) cells to cisplatin in vivo. We found that cancer patients with tumors expressing high Sox9 and low Fbw7 levels exhibit inferior survival. Our discovery reveals a novel function of SOX9 in the cellular response to DNA damage. Induced degradation of SOX9 may be part of the protection mechanisms to maintain genomic stability. This new regulatory mechanism of the FBW7-SOX9 axis in cancer could have diagnostic and therapeutic implications. Citation Format: Xuehui Hong, Wenyu Liu, Ruipeng Song, Hiroyuki Inuzuka, Hatem E. Sabaawy, Katherine M. Morgan, Jamie J. Shah, Samuel F. Bunting, Xing Feng, Chi-Kwan Tsang, Zhiyuan Shen, X. F. Steven Zheng, LianXin Liu, Sharon R. Pine. FBW7 induces S-phase arrest caused by DNA double strand breaks through targeting SOX9 for proteasomal degradation. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4544.

Supplementary Figure 2 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Supplementary Figure 1 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Supplemental Figure 4 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Supplementary Figure 6 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Supplementary Figure 5 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Data from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination.

Table S4 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

Table S2 from FBXO24 Suppresses Breast Cancer Tumorigenesis by Targeting LSD1 for Ubiquitination

LSD1 Destabilizes FBXW7 and Abrogates FBXW7 Functions Independent of Its Demethylase Activity

LSD1 Destabilizes FBXW7 Independent of Its Demethylase Activity

LSD1 Knockdown Reveals Novel Histone Lysine Methylation in Human Breast Cancer MCF-7 Cells

Supplementary Figure 1 from Binding of the JmjC Demethylase JARID1B to LSD1/NuRD Suppresses Angiogenesis and Metastasis in Breast Cancer Cells by Repressing Chemokine CCL14

The Deubiquitinase USP28 Stabilizes LSD1 and Confers Stem-Cell-like Traits to Breast Cancer Cells

LSD1 Promotes Prostate Cancer Cell Survival by Destabilizing FBXW7 at Post-Translational Level

Supplementary Data from FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression

OTUD7B Deubiquitinates LSD1 to Govern Its Binding Partner Specificity, Homeostasis, and Breast Cancer Metastasis

Targeting FBXO22 enhances radiosensitivity in non-small cell lung cancer by inhibiting the FOXM1/Rad51 axis

E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination

Abstract 4544: FBW7 Induces S-phase Arrest Caused by DNA Double Strand Breaks Through Targeting SOX9 for Proteasomal Degradation